ClinicalTrials.gg
RecruitingNCT06029192Updated Sep 8, 2023

Diastolic Function in Myotonic Dystrophy Type 1

An observational study in Diastolic Dysfunction, sponsored by Centre d'Investigation Clinique et Technologique 805. Recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2023-09-08.

Sponsored by Centre d'Investigation Clinique et Technologique 805 · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2023, 3 years 1 month ago, but the record still lists the study as recruiting.
  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
500
Sex
All
01

Study summary

Myotonic dystrophy type 1 (DM1) is a neuromuscular disorder in relation with an unstable expansion of CTG repeat. Patients with DM1 are at risk of arrhythmia and conduction disorders. Mortality are mainly related to respiratory failure and sudden death. Patients with DM1 may suffer from obesity, arterial hypertension, diabetes mellitus and sleep apnea. These comorbidities are classically associated with left ventricular diastolic dysfunction (DD) .

The investigators aim to assess the prevalence of left ventricular diastolic dysfunction in patients with myotonic dystrophy type 1 , the distribution of DD grading as well as the long-term prognosis of DM1 patients with a left ventricular diastolic dysfunction.

02

Conditions studied

  • Diastolic Dysfunction
03

In context

Lead sponsor

Centre d'Investigation Clinique et Technologique 805 is the lead sponsor of 75 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Sampling method
Non-probability sample

Study population

patients with myotonic dystrophy type 1 followed in a tertiary reference center.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with genetic proven myotonic dystrophy type 1
  • who experienced a Doppler- Echocardiography including an assessment of the left ventricular diastolic function

Exclusion criteria

Exclusion Criteria:

  • wall motion basal abnormalities
  • significant valvular disease
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
500 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. mortality

    Time frame: 7 years

Secondary outcomes

  1. Incidence of arrhythmia

    Time frame: 7 years

  2. acute heart failure

    Time frame: 7 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2023 (actual). Primary completion is estimated for Oct 2023, 4 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2023
First posted
Sep 8, 2023
StartActual
Jun 2, 2023
Primary completionEst.
Oct 2, 2023
CompletionEst.
Nov 1, 2023
Last update
Sep 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06029192
Lead sponsor
Centre d'Investigation Clinique et Technologique 805
Responsible party
Abdallah FAYSSOIL (Associate Professor, Centre d'Investigation Clinique et Technologique 805) — Principal investigator
First posted
Sep 8, 2023
Start date
Jun 2, 2023
Primary completion
Oct 2, 2023 (estimated)
Completion
Nov 1, 2023 (estimated)
Last update
Sep 8, 2023

Study contacts

Abdallah FAYSSOIL, MD PhD
Contact
abdallah.fayssoil@aphp.fr
+33147107778
Abdallah FAYSSOIL, MD PhD
principal investigator · CHU Raymond Poincare

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion